Access to anti-retroviral drugs, male in Indonesia

Indonesia: Access to anti-retroviral drugs, male was 44.0% in 2024. ◆ Volatile

Latest (2024)
44.0%
Change on year
up 33.3%
World rank
126th
of 141 countries
All-time high
44.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Indonesia, 2000–2024

0102030402000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 0 %2006: 2 %2007: 2 %2008: 3 %2009: 4 %2010: 4 %2011: 5 %2012: 6 %2013: 7 %2014: 9 %2015: 11 %2016: 13 %2017: 16 %2018: 19 %2019: 22 %2020: 25 %2021: 27 %2022: 30 %2023: 33 %2024: 44 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, male in Indonesia is 44.0%, measured in 2024. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 33.3% on the previous year and up 388.9% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Indonesia peaked at 44.0% in 2024 and was at its lowest, 0.0%, in 2000.

Indonesia ranks 126th of 141 countries on this measure, in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Indonesia, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Indonesia, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 0.0%
2006 2.0%
2007 2.0% +0.0%
2008 3.0% +50.0%
2009 4.0% +33.3%
2010 4.0% +0.0%
2011 5.0% +25.0%
2012 6.0% +20.0%
2013 7.0% +16.7%
2014 9.0% +28.6%
2015 11.0% +22.2%
2016 13.0% +18.2%
2017 16.0% +23.1%
2018 19.0% +18.8%
2019 22.0% +15.8%
2020 25.0% +13.6%
2021 27.0% +8.0%
2022 30.0% +11.1%
2023 33.0% +10.0%
2024 44.0% +33.3%

Averages by decade

DecadeAverage LowestHighest Years
2000s 1.1% 0.0% 4.0% 10
2010s 11.2% 4.0% 22.0% 10
2020s 31.8% 25.0% 44.0% 5

Countries ranked near Indonesia

  1. 125 Bangladesh 45.0% compare
  2. 126 Egypt 44.0% compare
  3. 128 Mongolia 42.0% compare
  4. 128 Philippines 42.0% compare

See the full ranking of 160 places →

More gender data for Indonesia

All data for Indonesia →

Frequently asked questions

What is access to anti-retroviral drugs, male in Indonesia?
Access to anti-retroviral drugs, male in Indonesia was 44.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Indonesia?
The highest recorded value was 44.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Indonesia?
The lowest recorded value was 0.0% in 2000.
How does Indonesia rank for access to anti-retroviral drugs, male?
Indonesia ranks 126th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Indonesia?
Over the last ten years it is up 388.9%. The long-run trend across the full record is volatile.
Where does this Indonesia data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Indonesia. Statizoid, drawing on UNAIDS estimates. Retrieved 10 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/indonesia/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/indonesia/">Access to anti-retroviral drugs, male in Indonesia</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.